Maternal deaths following nevirapine-based antiretroviral therapy

Southern African Journal of HIV Medicine

Volumn 13, Issue 4, 2012, Pages 196-197

  Bera, E ^a   Naidoo, D ^a   Williams, M ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

INOTROPIC AGENT; LAMIVUDINE; NEVIRAPINE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DRUG FATALITY; FEMALE; FETUS DEATH; FETUS ECHOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL MORTALITY; STILLBIRTH;

EID: 84873853793     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.7196/SAJHIVMED.869     Document Type: Article

References (17)

1. Goga A, Dinh TH, Jackson D, et al. Impact of the National Prevention of Mother to Child Transmission of HIV (PMTCT) Program on Perinatal Mother-to-Child Transmission of HIV (MTCT) Measured at 6 weeks Postpartum, South Africa (SA): Results of the First Year of Implementation of the 2010 PMTCT Guidelines recommended by the World Health Organization (WHO). IAC Conference, Pretoria, 26 July 2012.
2. Doherty T. PMTCT Indicators. The District Health Barometer 2007/8. Pretoria: Health Systems Trust, 2008. http://www.hst.org.za (accessed 20 January 2010).
3. National Committee for Confidential Enquiry into Maternal Deaths. Saving Mothers 2008 - 2010. Fifth Report on the Confidential Enquiries into Maternal Deaths in South Africa. Pretoria: Department of Health, 2012.
4. National Department of Health (DoH). Clinical Guidelines: PMTCT (Prevention of Mother-to-Child Transmission) 2010. Pretoria: DoH, 2010.
5. Ford N, Vitoria M, Shaffer N. Technical Update On Treatment Optimization. Use Of Efavirenz During Pregnancy: A Public Health Perspective. Geneva: World Health Organization, 2012.
6. Lewis-Hall FC. Important Change in SUSTIVA (efavirenz) Package Insert - Change from Category C to D. Rockville: Bristol-Myers Squibb Company, 2005. http://www.fda.gov (accessed 19 April 2008).
7. Schanske AL. Bilateral oblique facial clefts and extremity anomaly in an infant after intrauterine efavirenz exposure and review of its teratogenic risk. AIDS 2012 (in press). [http://dx.doi.org/10.1097/QAD.0b013e328356467a]
8. De Lazzari E, Leon A, Arnaiz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008;9:221-226. [http://dx.doi.org/10.1111/j.1468-1293.2008.00552.x]
9. McKoy JM, Bennett CL, Scheetz MH, et al. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: A systematic review and meta-analysis from the Research on Adverse Drug Events And Reports (RADAR) project. Drug Saf 2009;32(2):147-158. [http://dx.doi.org/10.2165/00002018- 200932020-00007]
10. Peters PJ, Polle N, Zeh C, et al. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya. J Int Assoc Physicians AIDS Care 2012;11:142-149. [http://dx.doi.org/10.1177/1545109711423445]
11. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1&z.ast;01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008;22(4):540-541. [http://dx.doi.org/10.1097/QAD.0b013e3282f37812]
12. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007;21(2):264-265. [http://dx.doi.org/10. 1097/QAD.0b013e32801199d9]
13. Caixas U, Antunes AMM, Marinho AT, et al. Evidence for nevirapine bioactivation in man: Searching for the first step in the mechanism of nevirapine toxicity. Toxicology 2012 (in press). [http://dx.doi.org/10.1016/j. tox.2012.06.013]
14. De Ruiter A, Taylor GP, Palfreeman A, et al. British HIV Association Guidelines for the Management of HIV Infection in Pregnant Women 2012: Consultation Draft. http://www.bhiva.org/documents/Guidelines/Pregnancy/ Pregnancy-Guidelines-for-Consultation120125.pdf (accessed 1 February 2012).
15. Mbuagbaw LCE, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviralnaive individuals. Cochrane Database of Systematic Reviews 2010;12.
16. Moore KL, Persaud TVN, Eds. The Developing Human: Clinically Orientated Embryology. 5th ed. Philadelphia: WB Saunders, 1993:205-225.
17. Robertson HL, Steyn NP, Venter PA, Christianson AL. Neural tube defects and folic acid: A South African perspective. S Afr Med J 1997;87:928-931.